Cardiovascular adverse events after the first dose of Gilenya®  ​​

Risk of developing abnormal changes in the electrical activity of the heart ​​

Reports of severe infectious endophthalmitis following unapproved intravitreal injection use ​

Risk of bladder cancer ​

Risk of QTc prolongation ​